Coloplast

Multiple silver linings in spite of a soft Q2 24

15/05/24 -"Coloplast reported softer than expected Q2 24 figures. However, with healthy organic growth, the miss reflected FX headwinds, and, hence, was not that worrisome. Importantly, growth was strong across ..."

PDF page sample
Pages
64
Language
English
Published on
15/05/24
Download
You may also be interested by these reports :
27/11/25
We have lowered our target price to reflect the business challenges outlined in the EPS section. Additionally, we have adjusted the peer-based ...
26/11/25
While Q2 sales slightly missed market expectations, Elekta’s Q2 profitability surpassed forecasts, despite tariff impacts and FX headwinds. Improved ...
14/11/25
Sonova reported decent H1 results, with sales aligning with the company-compiled consensus. However, normalised EBITA did not meet expectations due ...
13/11/25
The Q3 results were somewhat ahead of expectations, and the 2025 guidance was maintained this time, after two downgrades earlier this year. This, ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO